Achillion Pharmaceuticals reports that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a Phase 1 clinical trial re Achillion’s simeprevir and odalasvir.

As previously announced, Achillion has granted Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize products and regimens containing one or more of Achillion’s hepatitis C virus assets.

The hepatitis C virus is one of the most common causes of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including more than 5 million people in the United States.